Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
about
Future therapeutic targets in rheumatoid arthritis?The Plasticity of Th17 Cells in the Pathogenesis of Rheumatoid ArthritisInterleukin-17A is involved in mechanical hyperalgesia but not in the severity of murine antigen-induced arthritisRegulatory effects of zinc on cadmium-induced cytotoxicity in chronic inflammation.Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.What are the dominant cytokines in early rheumatoid arthritis?Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications.The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling.Shifting the Focus: The Primary Role of IL-23 in Psoriasis and other Inflammatory Disorders.When worlds collide: Th17 and Treg cells in cancer and autoimmunity.Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.
P2860
Q33841419-C092DCCB-B466-4B7B-B21C-B7428A762A7BQ39429529-296D94AC-05F9-4245-AC58-0739B31F6498Q41607103-2637EA54-29A1-4028-9CB9-CF7C4729AC1EQ42337048-A235EB2F-9719-4AB1-B5D4-FCD08162312CQ46750795-B9B61346-F32A-4025-97B6-57BABBC0A859Q47338654-42A4A874-7D4E-4D38-87DB-EB142E3D370DQ47366363-B4C685D4-5078-48AB-AAE0-E91F708D219AQ47727612-4B7DFB45-BDA6-4348-9F43-AB9996F93097Q47800990-39A2D682-D408-4A4B-82A2-7DCEB6A865AAQ48283709-1CA5C04A-AF92-48AB-A3DD-3EA286774D13Q50041283-9F2A1C80-539C-4CCB-9946-5FBD5EF6690FQ52689973-228562F0-38D4-4772-BE83-1A29BA8009A9Q55025616-F1133272-9E84-4FF7-9FBF-FC173DD8937B
P2860
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Secukinumab in Active Rheumato ...... and Placebo-Controlled Study.
@en
Secukinumab in Active Rheumato ...... and Placebo-Controlled Study.
@nl
type
label
Secukinumab in Active Rheumato ...... and Placebo-Controlled Study.
@en
Secukinumab in Active Rheumato ...... and Placebo-Controlled Study.
@nl
prefLabel
Secukinumab in Active Rheumato ...... and Placebo-Controlled Study.
@en
Secukinumab in Active Rheumato ...... and Placebo-Controlled Study.
@nl
P2093
P2860
P356
P1476
Secukinumab in Active Rheumato ...... - and Placebo-Controlled Study
@en
P2093
Christine Codding
Eva Dokoupilova
Hanno Richards
Jeffrey Neal
Mats Andersson
Rüdiger Möricke
Susanne Rohrer
P2860
P304
P356
10.1002/ART.40070
P577
2017-05-03T00:00:00Z